Wavelet Analysis of Electromyography (EMG) in Cerebral Palsy

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Shriners Hospitals for Children
ClinicalTrials.gov Identifier:
NCT00504049
First received: July 17, 2007
Last updated: July 21, 2010
Last verified: January 2009
  Purpose

Several methods exist to evaluate motor function in the child with cerebral palsy and are used to assess the outcome of a clinical intervention. However, these scales are not directed towards measuring the changes in muscle activity patterns that can result from the intervention. For example, there are classification scales aimed at measuring motor function and functional abilities, and indices of gait function. These scores, while providing a way to quantify function and mechanics, do not directly measure muscle activation characteristics. Therefore, these tests may be insensitive to how the intervention has directly affected muscle function, which is usually the focus of the intervention (i.e. botulinum toxin, functional electrical stimulation, dorsal rhizotomy). Muscle biopsies and motor evoked potentials can provide information about the muscle activation characteristics, however, they are invasive and there are concerns about using these techniques on the pediatric population and/or the practicality of clinical implementation, especially since they do not provide insight into how the muscle behaves during a functional task. One method that can be used to provide insight into muscle activity in a non-invasive and clinically meaningful manner is the use of surface electromyography (sEMG). Surface EMG is typically a routine part of clinical assessment and the evaluation of motor impairment in CP. However, the analysis of the data has been limited in most cases to examination of signal amplitude or differences in muscle onset and offset timing.

The long-term goal of this research is to develop an analysis method for sEMG that can be used during functional tasks for treatment planning, diagnostic, assessment purposes in CP. This is to be accomplished through the use of the continuous wavelet transform (CWT). By developing an assessment method based on muscle activity, it is believed that a clinically viable measurement tool can be devised that will provide a level of insight into the effects of an intervention on muscle pathophysiology that is not currently available. The first step in progressing towards this long-term goal is to determine the variability and range of expected time-frequency patterns that can be expressed in a given population (i.e., cerebral palsy) during the execution of a meaningful task (gait), and relate the time-frequency information back to more standard assessments


Condition
Cerebral Palsy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Wavelet Analysis of Surface EMG in Cerebral Palsy

Resource links provided by NLM:


Further study details as provided by Shriners Hospitals for Children:

Enrollment: 32
Study Start Date: March 2007
Study Completion Date: March 2009
  Eligibility

Ages Eligible for Study:   7 Years to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Children with spastic, diplegic cerebral palsy

Criteria

Inclusion Criteria:

  • A diagnosis of spastic diplegic CP
  • Must be ambulatory without the use of orthotics
  • Between a GMFCS Level I and Level III
  • Between the ages of 7 and 13 years
  • Cleared by an orthopedic surgeon for risk of hip subluxation or dislocation and cannot have significant scoliosis (curvature > 40 degrees)
  • Seizure-free or seizure controlled
  • Has visuoperceptual skills and cognitive/communication skills sufficient to follow multiple step commands and to attend to tasks associated with data collection
  • Must be greater than 1 year post-surgery to the lower extremities
  • Must be greater then 6 months botulinum toxin injection
  • Passive range of motion in lower extremity joints must be greater than 10 degrees of flexion contracture at the hips as measured by the Thomas Test, at least 20 degrees of hip abduction bilaterally, less than 5 degrees of knee flexion contracture, popliteal angle less than 45 degrees, and at least 0 degrees of ankle dorsiflexion with the knee extended while the foot is in varus

Exclusion Criteria:

  • Children who do not meet the inclusion criteria will not be considered for the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00504049

Locations
United States, Pennsylvania
Shriners Hospitals for Children
Philadelphia, Pennsylvania, United States, 19140
Sponsors and Collaborators
Shriners Hospitals for Children
Investigators
Principal Investigator: Richard T Lauer, PhD Shriners Hospitals for Children
  More Information

No publications provided

Responsible Party: Richard T. Lauer, Shriners Hospitals for Children
ClinicalTrials.gov Identifier: NCT00504049     History of Changes
Other Study ID Numbers: 1 R03 NS048875-01A2
Study First Received: July 17, 2007
Last Updated: July 21, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Shriners Hospitals for Children:
Cerebral Palsy
Electromyography
Wavelet Analysis

Additional relevant MeSH terms:
Paralysis
Cerebral Palsy
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Brain Damage, Chronic
Brain Diseases
Central Nervous System Diseases

ClinicalTrials.gov processed this record on September 29, 2014